R. Gallaschun

2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists.

Anne W. Schmidt, R. Obach, R. Mansbach, 2008, Journal of medicinal chemistry.

erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships.

P. Miller, C. Diorio, M. Dee, 1995, Journal of medicinal chemistry.

Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.

C. Diorio, M. Dee, J. Moyer, 1995, Journal of medicinal chemistry.

Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists.

Anne W. Schmidt, F. Tingley, T. Seeger, 2008, Journal of medicinal chemistry.

Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.

M. Corman, S. Winter, W. S. Faraci, 1997, Journal of medicinal chemistry.

Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.

A. Fliri, S. Mente, A. Schmidt, 2008, Bioorganic & medicinal chemistry letters.

Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice

Georg Rast, Bastian Hengerer, T. Strassmaier, 2018, PloS one.

Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiators.

J. Pandit, R. Hurst, M. Hajós, 2013, Journal of medicinal chemistry.